- Home
- ATLC vs BCAX Comparison
ATLC vs BCAX Comparison
Compare ATLC & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- BCAX
- Stock Information
- Founded
- ATLC 1996
- BCAX 2018
- Country
- ATLC United States
- BCAX United States
- Employees
- ATLC N/A
- BCAX N/A
- Industry
- ATLC Finance: Consumer Services
- BCAX
- Sector
- ATLC Finance
- BCAX
- Exchange
- ATLC Nasdaq
- BCAX NYSE
- Market Cap
- ATLC 732.1M
- BCAX 670.9M
- IPO Year
- ATLC 1999
- BCAX 2024
- Fundamental
- Price
- ATLC $49.05
- BCAX $9.25
- Analyst Decision
- ATLC Strong Buy
- BCAX Strong Buy
- Analyst Count
- ATLC 5
- BCAX 7
- Target Price
- ATLC $62.00
- BCAX $29.17
- AVG Volume (30 Days)
- ATLC 47.2K
- BCAX 1.1M
- Earning Date
- ATLC 05-08-2025
- BCAX 05-13-2025
- Dividend Yield
- ATLC N/A
- BCAX N/A
- EPS Growth
- ATLC 21.75
- BCAX N/A
- EPS
- ATLC 5.17
- BCAX N/A
- Revenue
- ATLC $424,877,000.00
- BCAX N/A
- Revenue This Year
- ATLC $270.55
- BCAX N/A
- Revenue Next Year
- ATLC $11.94
- BCAX N/A
- P/E Ratio
- ATLC $9.48
- BCAX N/A
- Revenue Growth
- ATLC 17.71
- BCAX N/A
- 52 Week Low
- ATLC $25.14
- BCAX $7.80
- 52 Week High
- ATLC $64.70
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- ATLC 41.02
- BCAX N/A
- Support Level
- ATLC $48.36
- BCAX N/A
- Resistance Level
- ATLC $49.80
- BCAX N/A
- Average True Range (ATR)
- ATLC 1.90
- BCAX 0.00
- MACD
- ATLC -0.55
- BCAX 0.00
- Stochastic Oscillator
- ATLC 23.48
- BCAX 0.00
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.